The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t(½) of approximately 24 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceriello, Antonio, De Nigris, Valeria, Iijima, Hiroaki, Matsui, Takahiro, Gouda, Maki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520312/
https://www.ncbi.nlm.nih.gov/pubmed/30982160
http://dx.doi.org/10.1007/s40265-019-01086-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520312/
https://www.ncbi.nlm.nih.gov/pubmed/30982160
http://dx.doi.org/10.1007/s40265-019-01086-0

Ejemplares similares